Evidence map›Paper›PMID 36037120›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines.

Najwa Al Balushi, Syed Imran Hassan, Nada Abdullah, Buthaina Al Dhahli, Shadia Al Bahlani, Ikhlas Ahmed, Benjamin K Tsang, Sergey Dobretsov, Yahya Tamimi, Ikram A Burney

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. How gallic acid regulates molecular signaling: role in cancer drug resistance.Medical oncology (Northwood, London, England) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Najwa Al BalushiDepartment of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, P. O. Box 35, PC 123, AlKhoud, Muscat, Oman.
Syed Imran HassanDepartment of Chemistry, College of Science, Sultan Qaboos University, P. O. Box 36, PC 123, AlKhoud, Muscat, Oman.ORCID 0000-0003-1839-184X
Nada AbdullahDepartment of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, P. O. Box 35, PC 123, AlKhoud, Muscat, Oman.
Buthaina Al DhahliDepartment of Allied Health Sciences, College of Medicine & Health Sciences, Sultan Qaboos University, P. O. Box 35, PC 123, AlKhoud, Muscat, Oman.
Shadia Al BahlaniDepartment of Allied Health Sciences, College of Medicine & Health Sciences, Sultan Qaboos University, P. O. Box 35, PC 123, AlKhoud, Muscat, Oman.
Ikhlas AhmedDepartment of Pharmacology and Clinical Pharmacy, College of Medicine & Health Sciences, Sultan Qaboos University, P. O. Box 35, PC 123, AlKhoud, Muscat, Oman.
Benjamin K TsangDepartments of Obstetrics & Gynecology, Cellular & Molecular Medicine and the Interdisciplinary School of Health Sciences, and the Centre for Infection, Immunity and Inflammation, University of Ottawa; Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0003-1213-3946
Sergey DobretsovDepartment of Marine Science & Fisheries, College of Agricultural & Marine Sciences, Sultan Qaboos University, P. O. Box 34, PC 123, AlKhoud, Muscat, Oman.ORCID 0000-0002-1769-6388
Yahya TamimiDepartment of Biochemistry, College of Medicine & Health Sciences, Sultan Qaboos University, P. O. Box 35, PC 123, AlKhoud, Muscat, Oman.
Ikram A BurneyDepartment of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, P. O. Box 35, PC 123, AlKhoud, Muscat, Oman.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOvarian cancer is one of the leading causes of cancer-related mortality in women, and is often associated with drug resistance. Therefore, finding effective drugs, including naturally derived compounds, is urgently needed. Herein, we aimed to test the anti-cancer potential of gallic acid monohydrate (GA) and its congeners on cisplatin-sensitive (A2780S), and resistant (A2780CP) ovarian cancer and normal ovarian (HOSE6-3) cell lines.

methodsCytotoxicity was assessed by AlamarBlue and CCK08 assays by exposing cells to different concentrations of cisplatin (0-21µg/mL), GA and its congeners (0-100µg/mL), and a combination of GA and cisplatin. Apoptosis was estimated by Hoechst stain and monitoring the relative RNA expression of the apoptotic effector caspase-3 using qRT-PCR.

resultsGA decreased cell viability in a concentration-dependent manner in all cell lines, with an IC50 of 19.39µg/mL (A2780S), 35.59 µg/mL (A2780CP), and 49.32µg/mL (HOSE6-3). GA displayed higher cytotoxicity than its congeners. An apoptotic rate estimation of approximately 20% and 30% was obtained in A2780S and A2780CP. While the cytotoxicity observed with cisplatin and GA was comparable, combining the two enhanced the cytotoxicity significantly, especially in the A2780CP cell line (p<0.05).

conclusionThese data suggest that GA may help overcome the resistance. Hence, the cytotoxic effects of GA, especially on chemo-resistant ovarian cancer cells merit further investigation.<br />.

Indexed as

Antineoplastic AgentsOvarian NeoplasmsApoptosisCarcinoma, Ovarian EpithelialCell Line, TumorCisplatinDrug Resistance, NeoplasmFemaleGallic AcidHumansAntineoplastic AgentsCisplatinGallic AcidChemo-resistanceCisplatinCytotoxicityGallic acidOvarian Cancer

Identifiers

PMID36037120
PMCPMC9741893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.